Core Insights - The article highlights the significant role of Beixin Life in the cardiovascular precision intervention solutions industry in China, emphasizing its pioneering efforts in promoting domestic clinical precision diagnosis for coronary artery diseases [2]. Company Overview - Beixin Life's initial public offering (IPO) price is set at 17.52 yuan, with a total market capitalization of 7.306 billion yuan [2]. - The company has a subscription rate of 0.03% for its IPO inquiry [2]. Business Highlights - Beixin Life is recognized as an industry leader in providing cardiovascular precision intervention solutions, being the first to innovate in this field within China [2]. - The core product, the FFR measurement system, captured a 30.6% market share in domestic indications in 2021, ranking second in the domestic market with a 10.4% overall market share [2]. - The company has a rich product pipeline with seven ongoing research projects aimed at iterative upgrades, including a radiofrequency ablation system that has entered the clinical trial phase [2]. - The controlling shareholder, Dr. Song Liang, possesses over 18 years of relevant research and development experience, and the core products have received awards for technological advancement and recognition as excellent domestic products [2].

2026年1月30日 深圳北芯生命科技股份有限公司（以下简称"北芯生命"、"发行人"或"公司"）首次公开发行人民币普通 股（以下简称"本次发行"）并在科创板上市的申请已经上海证券交易所（以下简称"上交所"）科创板上 市委员会审议通过，并已经中国证券监督管理委员会（以下简称"中国证监会"）同意注册（证监许可 〔２０２５〕２７９０号）。《深圳北芯生命科技股份有限公司首次公开发行股票并在科创板上市招股 说明书》在上海证券交易所网站（网址ｗｗｗ．ｓｓｅ．ｃｏｍ．ｃｎ）和符合中国证监会规定条件网 站（中国证券网，网址ｗｗｗ．ｃｎｓｔｏｃｋ．ｃｏｍ；中证网，网址ｗｗｗ．ｃｓ．ｃｏｍ．ｃ ｎ；证券时报网，网址ｗｗｗ．ｓｔｃｎ．ｃｏｍ；证券日报网，网址ｗｗｗ．ｚｑｒｂ．ｃｎ；经济 参考网，网址ｗｗｗ．ｊｊｃｋｂ．ｃｎ；中国金融新闻网，网址ｗｗｗ．ｆｉｎａｎｃｉａｌｎｅｗ ｓ．ｃｏｍ．ｃｎ；中国日报网，网址ｃｎ．ｃｈｉｎａｄａｉｌｙ．ｃｏｍ．ｃｎ）披露，并置备于 发行人、上交所、本次发行保荐人（主承销商）中国国际金融股份有限公司的住所，供公众查阅。 ■■ 发行人：深圳北芯生命科技股份有限公司 保荐人（主承销商）：中国国际金融股 ...

Group 1: North Chip Life (北芯生命) - North Chip Life is focused on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] - The company is a national high-tech enterprise and has developed China's first domestically innovative 60MHz high-definition IVUS product approved by the National Medical Products Administration [1] - The core product, the Fractional Flow Reserve (FFR) measurement system, is the first domestically produced product in the FFR field approved by the National Medical Products Administration [1] Group 2: Electric Science Blue Sky (电科蓝天) - Electric Science Blue Sky is engaged in the research, development, production, sales, and service of electric energy products and systems [2] - The company offers a complete set of solutions for power generation, energy storage, control, and system integration, with applications in major projects such as the Shenzhou series spacecraft and the Beidou navigation system [2] - The domestic market coverage of aerospace power products is expected to exceed 50% in 2024 [2] Group 3: Linping Development (林平发展) - Linping Development specializes in the research, development, production, and sales of corrugated paper and boxboard products [3] - The company is recognized as a high-tech enterprise with independent research and innovation capabilities [3] - Linping Development has evolved into a resource comprehensive utilization enterprise integrating waste paper utilization, cogeneration, and green papermaking [3]

Group 1 - The lawsuit is currently in the retrial phase, with the company as the plaintiff and the amount involved being 10,340,829 yuan [2] - The company has previously made full provisions for bad debts related to the advance payment to Hosheng Medical, and it plans to appeal the recent judgment [2][6] - The recent judgment from Huangpu Court has ruled to terminate the nine mold procurement contracts and rejected all claims from Hosheng Medical [4] Group 2 - The company has incurred litigation costs of 87,131.24 yuan for the main case and 41,922.49 yuan for the counterclaim, with additional costs for litigation preservation [4] - The company is unable to predict the impact of the recent judgment on its current and future profits [6] - The company will continue to monitor the case's progress and fulfill its information disclosure obligations [6]

Core Viewpoint - The company has received a medical device registration certificate for its drug-eluting stent system, which is expected to enhance its product portfolio and market competitiveness [1][4]. Group 1: Medical Device Registration - The registration certificate number is 国械注准20263130263, and the product is a drug-eluting stent system [1]. - The drug-eluting stent system consists of a drug-coated stent made from L605 cobalt-chromium alloy and a rapid exchange balloon catheter delivery system [1][3]. - The drug-coated stent features a non-degradable bottom coating made of poly(butyl methacrylate) (PBuMA) and a biodegradable drug coating composed of rapamycin and poly(lactic-co-glycolic acid) (PLGA) [1][3]. - The drug dosage density is 1.20 μg/mm², with a drug loading range of 59 μg to 324 μg [1]. Group 2: Product Specifications - The product is suitable for blood vessels with diameters ranging from 2.25 mm to 4.00 mm for lesions ≤40 mm, and for diameters of 4.50 mm to 5.00 mm for lesions ≤30 mm, aimed at improving symptoms of ischemic heart disease [2]. - The product has a shelf life of 18 months and is sterilized using electron beam technology for single use [1][3]. Group 3: Impact on the Company - The approval of the drug-eluting stent system represents a significant achievement in the company's R&D efforts and is expected to accelerate the commercialization of its products [4]. - This product will enrich the company's product offerings, meet diverse market demands, and enhance its core competitiveness [4]. - The product is classified as a Class III medical device, and further production licensing is required before manufacturing can commence [4].

Group 1 - The company has received notification from the EU regulatory body regarding the addition of multiple products to its Medical Device Regulation (MDR) certification [1] - The MDR certification indicates that the products comply with the latest EU medical device regulations, allowing for legal sales in relevant overseas markets [1] - The certification is expected to enhance the promotion and sales of the company's products in the corresponding markets [1] Group 2 - The actual sales performance of the newly certified products in overseas markets will depend on future marketing efforts, and the specific impact on the company's future operating performance remains unpredictable [1]

Core Viewpoint - The company is currently involved in a legal dispute with Shenzhen Hosheng Medical Technology Co., Ltd. regarding a mold procurement contract, with a total claim amount of 10,340,829 yuan and additional losses of 644,911 yuan [2][3]. Group 1: Litigation Status - The case is at the stage of retrial in the first instance [2]. - The company is the plaintiff (and counter-defendant) in this litigation [2]. - The company has previously fully provided for bad debts related to the advance payment to Hosheng Medical [2][5]. Group 2: Background of the Litigation - The company filed a lawsuit against Hosheng Medical in August 2022 due to disputes over nine mold procurement contracts signed between November 2020 and January 2021 [3]. - In March 2023, the Huangpu Court ruled to terminate the contracts and ordered Hosheng Medical to refund the payment and compensate for losses, but Hosheng Medical appealed the decision [3]. - In March 2024, the Guangzhou Intermediate People's Court annulled the original ruling and sent the case back for retrial [3]. Group 3: Retrial Judgment - The Huangpu Court recently issued a civil judgment, which includes the termination of the contracts and rejection of the company's other claims, while also dismissing all claims from Hosheng Medical [4]. - The company is responsible for the litigation costs amounting to 87,131.24 yuan for the main case and 5,000 yuan for litigation preservation [4]. Group 4: Future Implications - The company plans to appeal the recent judgment, but it is currently unable to estimate the impact on its profits for the current and future periods [5]. - The company will continue to monitor the case's progress and fulfill its information disclosure obligations [5].

Core Viewpoint - Sino Medical has received the Medical Device Registration Certificate for its drug-eluting stent system, marking a significant milestone in its product development and commercialization efforts [2][4]. Group 1: Medical Device Registration Details - The product is a drug-eluting stent system composed of a drug-coated stent and a rapid exchange balloon catheter delivery system [2]. - The stent is made from L605 cobalt-chromium alloy and features a non-degradable bottom coating and a biodegradable drug coating containing rapamycin and PLGA [2][3]. - The drug dosage density is 1.20 μg/mm², with a drug loading range of 59 μg to 324 μg [2]. Group 2: Product Specifications and Usage - The stent is designed for use in blood vessels with diameters ranging from 2.25 mm to 5.00 mm and is intended to alleviate symptoms of ischemic heart disease [2][3]. - The product has a shelf life of 18 months and is sterilized using electron beam technology for single-use [2]. Group 3: Impact on the Company - The approval of the drug-eluting stent system enhances the company's product portfolio and is expected to meet diverse market demands, potentially boosting sales and core competitiveness [4]. - The product is classified as a Class III medical device, requiring further production licensing before it can be manufactured and sold [4].

Core Insights - The article highlights the emergence of Chinese high-end medical equipment manufacturers, particularly United Imaging, as key players in the global market, showcasing their advanced technologies and products [1][2]. Group 1: Company Overview - United Imaging has developed several world-first medical devices, including a 2-meter PET-CT and a 5.0T full-body MRI, demonstrating its growth and the evolution of China's high-end medical equipment industry [1]. - The company has transitioned from being a mere assembler to a leader in the high-end imaging equipment market, previously dominated by international giants like GE, Philips, and Siemens [1]. Group 2: Technological Innovation - United Imaging's success is attributed to its commitment to mastering core technologies, guided by its principle of "three musts": comprehensive coverage, independent research and development, and alignment with international standards [2]. - The company has established over 40 regional headquarters and subsidiaries globally, focusing on localizing its research, production, and marketing efforts to enhance its global presence [2]. Group 3: Industry Impact - Under China's "14th Five-Year Plan," United Imaging is positioned as a leading enterprise that will drive significant growth in the medical device sector, emphasizing the integration of innovation across various chains [3]. - The company's journey from a startup in Shanghai to a global leader exemplifies the importance of independent innovation and the necessity of holding core technologies within the company [3].

Core Viewpoint - Southbound funds reduced their holdings in MicroPort Scientific Corporation (00853.HK) by 3.83 million shares on February 4, indicating a fluctuation in investor sentiment towards the company [1] Group 1: Southbound Fund Activity - Over the past five trading days, southbound funds increased their holdings on three occasions, with a total net increase of 117,100 shares [1] - In the last twenty trading days, there were fourteen days of net increases, totaling 25.75 million shares [1] - Currently, southbound funds hold 926 million shares of MicroPort, representing a significant portion of the company's issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]